Last reviewed · How we verify
Treatment (Viibryd)
Viibryd is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases serotonin and norepinephrine levels in the brain to treat depression.
Viibryd is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases serotonin and norepinephrine levels in the brain to treat depression. Used for Major depressive disorder.
At a glance
| Generic name | Treatment (Viibryd) |
|---|---|
| Also known as | Vilazodone |
| Sponsor | Southern California Institute for Research and Education |
| Drug class | Serotonin-norepinephrine reuptake inhibitor (SNRI) with 5-HT1A partial agonist activity |
| Target | Serotonin transporter (SERT); 5-HT1A receptor (partial agonist) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Mental Health |
| Phase | FDA-approved |
Mechanism of action
Viibryd (vilazodone) blocks the reuptake of serotonin at the serotonin transporter and also has partial agonist activity at the 5-HT1A receptor. This dual mechanism increases synaptic serotonin availability while the 5-HT1A agonism may enhance antidepressant efficacy and potentially reduce sexual dysfunction compared to traditional SSRIs.
Approved indications
- Major depressive disorder
Common side effects
- Nausea
- Diarrhea
- Dizziness
- Insomnia
- Somnolence
- Dry mouth
Key clinical trials
- Department of Defense PTSD Adaptive Platform Trial - Master Protocol (PHASE2)
- A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy (PHASE2)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Double-Blind Treatment of Major Depressive Disorder With Vilazodone (PHASE2)
- Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder (PHASE3)
- Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder (PHASE3)
- Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder (PHASE3)
- Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment (Viibryd) CI brief — competitive landscape report
- Treatment (Viibryd) updates RSS · CI watch RSS
- Southern California Institute for Research and Education portfolio CI